Prediction of Treatment Efficacy in Psoriasis Vulgaris Using Dermoscopic and Capillaroscopic Findings: a Prospective Cohort Study

Overview

Journal Arch Dermatol Res

Date 2025 Jan 13

PMID 39804498

Authors

Muhammet Resat Akkus

Kemal Ozyurt

Mustafa Atasoy

Ragip Ertas

Huzeyfe Kulu

Sinem Sogancioglu Ozata

Abdullah Demirbas

Omer Faruk Elmas

Esin Diremsizoglu

Affiliations

Soon will be listed here.

Abstract

Introduction: Psoriasis is a chronic inflammatory skin disorder affecting millions worldwide. Dermoscopy and proximal nailfold capillaroscopy have emerged as valuable tools for understanding the pathophysiology and treatment response of psoriasis lesions.

Objectives: This study aimed to contribute to the limited literature on using dermoscopic findings to detect treatment effectiveness in patients with psoriasis vulgaris.

Methods: This prospective, single-blinded, observational cohort study included 101 patients aged 18-71 years diagnosed with psoriasis vulgaris who initiated or altered systemic treatment. Monthly dermoscopic and capillaroscopic evaluations were performed alongside assessments of Psoriasis Area Severity Index (PASI), Body Surface Area (BSA), and Dermatology Life Quality Index (DLQI) scores.

Results: A significant relationship was found between first-month dermoscopic findings and third-month severity scores (PASI, BSA, DLQI). Patients with positive treatment responses exhibited changes from baseline regular capillary dilations to hemorrhagic spots or the absence of vascular findings during the first month. The correlations between dermoscopic changes and severity scores evolved over time, becoming stronger in the second and third months. Nailfold capillaroscopy findings at the third month of treatment showed significant differences from baseline.

Conclusions: Dermoscopy is a fast, practical, and inexpensive tool for early prediction of treatment effectiveness in psoriasis vulgaris. The disappearance of regular capillary dilations or their change to hemorrhagic spots suggests treatment efficacy, while their persistence indicates poor treatment response. Early detection of treatment effectiveness using dermoscopic findings can facilitate timely adjustments, improving patient outcomes and reducing unnecessary treatment exposure.

References

Lallas A, Zalaudek I, Argenziano G, Longo C, Moscarella E, Di Lernia V . Dermoscopy in general dermatology. Dermatol Clin. 2013; 31(4):679-94, x. DOI: 10.1016/j.det.2013.06.008. View

Micali G, Lacarrubba F, Massimino D, Schwartz R . Dermatoscopy: alternative uses in daily clinical practice. J Am Acad Dermatol. 2011; 64(6):1135-46. DOI: 10.1016/j.jaad.2010.03.010. View

Lallas A, Giacomel J, Argenziano G, Garcia-Garcia B, Gonzalez-Fernandez D, Zalaudek I . Dermoscopy in general dermatology: practical tips for the clinician. Br J Dermatol. 2013; 170(3):514-26. DOI: 10.1111/bjd.12685. View

Lallas A, Kyrgidis A, Tzellos T, Apalla Z, Karakyriou E, Karatolias A . Accuracy of dermoscopic criteria for the diagnosis of psoriasis, dermatitis, lichen planus and pityriasis rosea. Br J Dermatol. 2012; 166(6):1198-205. DOI: 10.1111/j.1365-2133.2012.10868.x. View

Gniadecki R, Kragballe K, Dam T, Skov L . Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol. 2011; 164(5):1091-6. DOI: 10.1111/j.1365-2133.2011.10213.x. View

Sivasankari M, Arora S, Vasdev V, Mary E . Nailfold capillaroscopy in psoriasis. Med J Armed Forces India. 2021; 77(1):75-81. PMC: 7809563. DOI: 10.1016/j.mjafi.2020.01.013. View

Vazquez-Lopez F, Zaballos P, Fueyo-Casado A, Sanchez-Martin J . A dermoscopy subpattern of plaque-type psoriasis: red globular rings. Arch Dermatol. 2007; 143(12):1612. DOI: 10.1001/archderm.143.12.1612. View

Stinco G, Lautieri S, Valent F, Patrone P . Cutaneous vascular alterations in psoriatic patients treated with cyclosporine. Acta Derm Venereol. 2007; 87(2):152-4. DOI: 10.2340/00015555-0216. View

Lallas A, Argenziano G, Zalaudek I, Apalla Z, Ardigo M, Chellini P . Dermoscopic hemorrhagic dots: an early predictor of response of psoriasis to biologic agents. Dermatol Pract Concept. 2016; 6(4):7-12. PMC: 5108638. DOI: 10.5826/dpc.0604a02. View

10.

Pathirana D, Ormerod A, Saiag P, Smith C, Spuls P, Nast A . European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009; 23 Suppl 2:1-70. DOI: 10.1111/j.1468-3083.2009.03389.x. View

11.

Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58(5):826-50. DOI: 10.1016/j.jaad.2008.02.039. View

12.

Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009; 60(4):643-59. DOI: 10.1016/j.jaad.2008.12.032. View

13.

Menter A, Korman N, Elmets C, Feldman S, Gelfand J, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011; 65(1):137-74. DOI: 10.1016/j.jaad.2010.11.055. View